• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Multi-stage evaluation and revision of information materials on the mammography screening programme]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2024     NIHR Health Services and Delivery Research programme Causes and solutions to workplace psychological ill-health for nurses, midwives and paramedics: the Care Under Pressure 2 realist review
2024     The Danish Health Technology Council (DHTC) [Assessment of domiciliary non-invasive ventilation for patients with chronic obstructive pulmonary disease]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: equivalence of the positivity threshold of immunochemical fecal occult blood tests for colorectal cancer screening]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Portable automated sputum suction]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Patient specific aortic graft guidance for open thoracoabdominal aortic repair]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Migraine surgery]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endorectal cooling accompanying prostate cancer surgery]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endoscopic anti-reflux mucosectomy, ARMS]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Resuscitative endovascular balloon occlusion of the aorta]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Algorithm-based Alzheimer's disease diagnosis-aided test using plasma biomarkers]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Irreversible electroporation for renal cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Gastrointestinal bleeding control using endoscopic hemostatic powder]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Monocyte distribution width, MDW]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based screening test for emergent large vessel occlusion using non-contrast brain CT images]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for paroxysmal atrial fibrillation using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Less invasive surfactant administration]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of prostatic hyperplasia]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Emotional freedom technique]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Radiofrequency catheter ablation using in-silico modelling in atrial fibrillation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endograft fixation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Laparoscopic and endoscopic cooperative surgery for gastrointestinal tumor]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for acute myocardial infarction using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Markerless real-time monitoring surface guided radiation therapy]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Seoul Cognitive Status Test]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Autologous platelet rich fibrin therapy to promote wound healing]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [von Willebrand Factor collagen binding activity [high quality immunoassay]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Intraoperative CT imaging system for navigational spine surgery]
2024     NIHR Health and Social Care Delivery Program Relationship between staff and quality of care in care homes: StaRQ mixed methods study
2024     NIHR Health Technology Assessment programme Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study
2024     NIHR Health Technology Assessment programme Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis
2024     HTA Region Stockholm [Comparing coronary computed tomography angiography (CCTA) to exercise electrocardiogram for suspected coronary artery disease: impact on patient outcomes]
2024     HTA Region Stockholm [Effectiveness of intravesical instillation for overactive bladder including bladder pain syndrome]
2024     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer. NICE technology appraisal guidance 944
2024     National Institute for Health and Care Excellence (NICE) Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2024     National Institute for Health and Care Excellence (NICE) Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946
2024     National Institute for Health and Care Excellence (NICE) Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2024     National Institute for Health and Care Excellence (NICE) Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2024     National Institute for Health and Care Excellence (NICE) Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2024     National Institute for Health and Care Excellence (NICE) Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2024     National Institute for Health and Care Excellence (NICE) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2024     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2024     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 954
2024     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 955
2024     National Institute for Health and Care Excellence (NICE) Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. NICE technology appraisal guidance 956
2024     National Institute for Health and Care Excellence (NICE) Momelotinib for treating myelofibrosis-related splenomegaly or symptoms. NICE technology appraisal guidance 957
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2024     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2024     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2024     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2024     National Institute for Health and Care Excellence (NICE) Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 964
2024     National Institute for Health and Care Excellence (NICE) Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal). NICE technology appraisal guidance 965
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024     Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C: a short report update
2024     Health Information and Quality Authority (HIQA) Review of national rare disease strategies in selected countries
2024     Health Technology Wales (HTW) Liposuction for the treatment of chronic lymphoedema
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for hip joint replacement]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegunigalsidase alfa (Fabry disease) – Addendum to Project A23-95]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palopegteriparatide (chronic hypoparathyroidism) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone for DLBCL – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: development and evaluation of a software tool based on GPT-4 to help sort documents for literature reviews - a proof of concept]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: non-physician prescribers' scope of practice]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) [Onnikka® lifestyle intervention application for weight management]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) [eConsultation – a digital service centre]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) StellarQ-platform (user interface for professionals)
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024     Ontario Health Intrathecal drug delivery systems for cancer pain